相似文献
1
Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy.
Expert Rev Vaccines. 2015;14(9):1255-75.
2
The immunotherapeutic effects of recombinant Bacillus Calmette-Guérin resistant to antimicrobial peptides on bladder cancer cells.
Biochem Biophys Res Commun. 2019 Jan 29;509(1):167-174. doi: 10.1016/j.bbrc.2018.12.097. Epub 2018 Dec 20.
3
Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes.
Vaccine. 2017 Mar 14;35(12):1599-1607. doi: 10.1016/j.vaccine.2017.02.024. Epub 2017 Feb 20.
4
A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Appl Microbiol Biotechnol. 2015 Dec;99(24):10587-95. doi: 10.1007/s00253-015-6962-x. Epub 2015 Sep 12.
5
Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer.
Clin Dev Immunol. 2011;2011:728930. doi: 10.1155/2011/728930. Epub 2011 Sep 15.
6
Recombinant Mycobacterium bovis BCG.
Vaccine. 2009 Nov 5;27(47):6495-503. doi: 10.1016/j.vaccine.2009.08.044. Epub 2009 Aug 29.
7
MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Expert Opin Biol Ther. 2010 Jul;10(7):1037-48. doi: 10.1517/14712598.2010.485185.
8
Recombinant BCG vaccine candidates.
Curr Mol Med. 2007 Jun;7(4):365-72. doi: 10.2174/156652407780831610.
9
Recombinant BCG Expressing Mycobacterium ulcerans Ag85A Imparts Enhanced Protection against Experimental Buruli ulcer.
PLoS Negl Trop Dis. 2015 Sep 22;9(9):e0004046. doi: 10.1371/journal.pntd.0004046. eCollection 2015 Sep.
10
Bacillus Calmette-Guérin strain differences as the basis for immunotherapies against bladder cancer.
Int J Urol. 2018 May;25(5):405-413. doi: 10.1111/iju.13538. Epub 2018 Mar 5.
引用本文的文献
1
The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response.
Am J Transl Res. 2023 Jun 15;15(6):3960-3975. eCollection 2023.
2
Prognostic Signature GXYLT2 Is Correlated with Immune Infiltration in Bladder Cancer.
Dis Markers. 2022 Oct 10;2022:5081413. doi: 10.1155/2022/5081413. eCollection 2022.
3
Vitamin B6 Antidepressant Effects Are Comparable to Common Antidepressant Drugs in Bacillus-Calmette-Guerin Induced Depression Model in Mice.
Iran J Psychiatry. 2022 Apr;17(2):208-216. doi: 10.18502/ijps.v17i2.8911.
4
CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer.
Cancers (Basel). 2022 Oct 5;14(19):4866. doi: 10.3390/cancers14194866.
5
Novel molecules as the emerging trends in cancer treatment: an update.
Med Oncol. 2022 Jan 4;39(2):20. doi: 10.1007/s12032-021-01615-6.
6
Positive QuantiFERON test and the severity of COVID-19 disease: A prospective study.
Indian J Tuberc. 2021 Oct;68(4):474-480. doi: 10.1016/j.ijtb.2020.12.013. Epub 2021 Mar 3.
7
The Diverse Applications of Recombinant BCG-Based Vaccines to Target Infectious Diseases Other Than Tuberculosis: An Overview.
Front Microbiol. 2021 Oct 21;12:757858. doi: 10.3389/fmicb.2021.757858. eCollection 2021.
8
Copy number variation analysis of m A regulators identified METTL3 as a prognostic and immune-related biomarker in bladder cancer.
Cancer Med. 2021 Nov;10(21):7804-7815. doi: 10.1002/cam4.3981. Epub 2021 Oct 20.
9
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
Int Immunopharmacol. 2021 Jul;96:107763. doi: 10.1016/j.intimp.2021.107763. Epub 2021 May 6.
10
Variances in BCG protection against COVID-19 mortality: A global assessment.
J Clin Tuberc Other Mycobact Dis. 2021 Aug;24:100249. doi: 10.1016/j.jctube.2021.100249. Epub 2021 Jun 6.
本文引用的文献
1
Nonclinical Development of BCG Replacement Vaccine Candidates.
Vaccines (Basel). 2013 Apr 16;1(2):120-38. doi: 10.3390/vaccines1020120.
2
Mycobacterium africanum is associated with patient ethnicity in Ghana.
PLoS Negl Trop Dis. 2015 Jan 8;9(1):e3370. doi: 10.1371/journal.pntd.0003370. eCollection 2015 Jan.
3
Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants.
J Infect Dis. 2015 Feb 1;211(3):338-46. doi: 10.1093/infdis/jiu434. Epub 2014 Aug 8.
4
Recombinant BCG: Innovations on an Old Vaccine. Scope of BCG Strains and Strategies to Improve Long-Lasting Memory.
Front Immunol. 2014 Apr 7;5:152. doi: 10.3389/fimmu.2014.00152. eCollection 2014.
5
Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Eur Urol. 2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.
6
Recent advances towards tuberculosis control: vaccines and biomarkers.
J Intern Med. 2014 May;275(5):467-80. doi: 10.1111/joim.12212.
7
In search of a new paradigm for protective immunity to TB.
Nat Rev Microbiol. 2014 Apr;12(4):289-99. doi: 10.1038/nrmicro3230. Epub 2014 Mar 3.
8
Differences in T-cell responses between Mycobacterium tuberculosis and Mycobacterium africanum-infected patients.
Eur J Immunol. 2014 May;44(5):1387-98. doi: 10.1002/eji.201343956. Epub 2014 Feb 20.
9
Treatment efficacy and tolerability of intravesical bacillus Calmette-Guerin (BCG)-RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC).
BMC Urol. 2014 Jan 27;14:11. doi: 10.1186/1471-2490-14-11.
10
1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.
Oncotarget. 2013 Dec;4(12):2397-406. doi: 10.18632/oncotarget.1494.
Zotero 插件